Federal Register / Vol. 90, No. 5 / Wednesday, January 8, 2025 / Notices 1499 

D In January 2024, CDC affirmed 

existing viral-first testing 

recommendations among people with 

recent HCV exposure (https://

www.cdc.gov/hepatitis-c/hcp/diagnosistesting/#:∼:text=HCV%20RNA%20

testing%20for,a%20

syringe%20service%20program); 

D In January 2024, CDC began the 

process of updating HCV testing 

guidance for clinicians and 

laboratorians, including evaluating 

testing strategies for the general 

population that include tests for viral 

markers in the first testing step (e.g., 

‘‘viral-first’’); and 

D In June 2024, the FDA authorized 

an HCV RNA CLIA-waived near pointof-care test for the diagnosis of current 

HCV infection. 

Public Participation and Public 

Comment 

Public engagement will entail listenonly observation of information shared 

on day 1 and day 2. If members of the 

public have input on the questions 

asked during the meeting, those public 

comments can be collected through 

regulations.gov using Docket CDC– 

2025–0002 on or before February 19, 

2025, and will be included in the final 

meeting report. Written comments must 

be submitted on or before February 19, 

2025. 

Please note that comments received, 

including attachments and other 

supporting materials, are part of the 

public record and are subject to public 

disclosure. Comments will be posted on 

https://www.regulations.gov. Therefore, 

do not include any information in your 

comment or supporting materials that 

you consider confidential or 

inappropriate for public disclosure. If 

you include your name, contact 

information, or other information that 

identifies you in the body of your 

comments, that information will be on 

public display. CDC will review all 

submissions and may choose to redact, 

or withhold, submissions containing 

private or proprietary information such 

as Social Security numbers, medical 

information, inappropriate language, or 

duplicate/near duplicate examples of a 

mass-mail campaign. Do not submit 

comments by email. CDC does not 

accept comment by email. 

Noah Aleshire, 

Chief Regulatory Officer, Centers for Disease 

Control and Prevention. 

[FR Doc. 2025–00204 Filed 1–7–25; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

[30Day–25–24FS] 

Agency Forms Undergoing Paperwork 

Reduction Act Review 

In accordance with the Paperwork 

Reduction Act of 1995, the Centers for 

Disease Control and Prevention (CDC) 

has submitted the information 

collection request titled ‘‘Needle 

Exchange Utilization Survey (NEXUS)’’ 

to the Office of Management and Budget 

(OMB) for review and approval. CDC 

previously published a ‘‘Proposed Data 

Collection Submitted for Public 

Comment and Recommendations’’ 

notice on May 28, 2024, to obtain 

comments from the public and affected 

agencies. CDC received one comment 

related to the previous notice. This 

notice serves to allow an additional 30 

days for public and affected agency 

comments. 

CDC will accept all comments for this 

proposed information collection project. 

The Office of Management and Budget 

is particularly interested in comments 

that: 

(a) Evaluate whether the proposed 

collection of information is necessary 

for the proper performance of the 

functions of the agency, including 

whether the information will have 

practical utility; 

(b) Evaluate the accuracy of the 

agencies estimate of the burden of the 

proposed collection of information, 

including the validity of the 

methodology and assumptions used; 

(c) Enhance the quality, utility, and 

clarity of the information to be 

collected; 

(d) Minimize the burden of the 

collection of information on those who 

are to respond, including, through the 

use of appropriate automated, 

electronic, mechanical, or other 

technological collection techniques or 

other forms of information technology, 

e.g., permitting electronic submission of 

responses; and 

(e) Assess information collection 

costs. 

To request additional information on 

the proposed project or to obtain a copy 

of the information collection plan and 

instruments, call (404) 639–7570. 

Comments and recommendations for the 

proposed information collection should 

be sent within 30 days of publication of 

this notice to www.reginfo.gov/public/ 

do/PRAMain. Find this particular 

information collection by selecting 

‘‘Currently under 30-day Review—Open 

for Public Comments’’ or by using the 

search function. Direct written 

comments and/or suggestions regarding 

the items contained in this notice to the 

Attention: CDC Desk Officer, Office of 

Management and Budget, 725 17th 

Street NW, Washington, DC 20503 or by 

fax to (202) 395–5806. Provide written 

comments within 30 days of notice 

publication. 

Proposed Project 

Needle Exchange Utilization Survey 

(NEXUS)—New—National Center for 

HIV, Viral Hepatitis, STD, and TB 

Prevention (NCHHSTP), Centers for 

Disease Control and Prevention (CDC). 

Background and Brief Description 

The opioid crisis in the U.S. has led 

to steep increases in overdose, Hepatitis 

C Virus (HCV) incidence, and HIV 

clusters and outbreaks among people 

who inject drugs (PWID). These 

alarming trends indicate an urgent need 

to strengthen interventions to prevent 

morbidity and mortality and 

transmission of infectious disease 

among PWID. Syringe services programs 

(SSPs) are evidence-based, highly 

effective prevention programs that have 

expanded in many areas in the United 

States to respond to the increasing 

needs of providing HIV and HCV 

prevention and other health and social 

services to PWID and their 

communities. Due to an increase in HCV 

and HIV related to injection drug use 

(IDU), it is now critical to understand 

current patterns of IDU for the 

prevention of these infectious diseases 

and other injection related harms. Data 

to inform these prevention efforts are 

needed nationally, particularly from 

non-urban settings that have 

experienced increases in IDU and where 

current surveillance activities are nonexistent or limited. 

The purpose of the Needle Exchange 

Utilization Survey (NEXUS) is to 

develop a surveillance system to 

monitor drug use, prevention behaviors, 

and the infectious disease consequences 

of drug use in 6–15 select urban and 

non-urban areas of the U.S. that the 

opioid crisis has impacted. Such a 

surveillance system is needed to inform 

prevention efforts and policy. The 

specific objectives of the project are to 

assess the following among persons who 

inject drugs who are recruited in SSPs 

and their peers who use drugs through 

peer-driven recruitment: (1) drug use 

and sexual behaviors, injection risk 

networks, receipt of prevention services, 

and barriers to prevention and care; and 

(2) the prevalence of HIV and HCV 

infections. 


lotter on DSK11XQN23PROD with NOTICES1
1500 Federal Register / Vol. 90, No. 5 / Wednesday, January 8, 2025 / Notices 

CDC requests OMB approval for an 

estimated 3,126 total annualized burden 

hours. Participation is voluntary and 

there are no costs to the respondents 

other than their time. 

ESTIMATED ANNUALIZED BURDEN HOURS

Respondent Form Number of 

respondents 

Number of 

responses per 

respondent 

Average 

burden per 

response 

(hours) 

Persons Screened .......................................... Eligibility Screening Form English ................. 5,400 1 5/60 

Persons Screened .......................................... Eligibility Screening Form Spanish ................ 600 1 5/60 

Persons who give permission ......................... Model Project Consent Form English ............ 4,050 1 5/60 

Persons who give permission ......................... Model Project Permission Form Spanish ...... 450 1 5/60 

Eligible Participants ......................................... NEXUS Survey English .................................. 4,050 1 30/60 

Eligible Participants ......................................... NEXUS Survey Spanish ................................ 450 1 30/60 

Jeffrey M. Zirger, 

Lead, Information Collection Review Office, 

Office of Public Health Ethics and 

Regulations, Office of Science, Centers for 

Disease Control and Prevention. 

[FR Doc. 2025–00159 Filed 1–7–25; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

[30 Day–25–1360] 

Agency Forms Undergoing Paperwork 

Reduction Act Review 

In accordance with the Paperwork 

Reduction Act of 1995, the Centers for 

Disease Control and Prevention (CDC) 

has submitted the information 

collection request titled ‘‘CryptoNet 

Case Report Form’’ to the Office of 

Management and Budget (OMB) for 

review and approval. CDC previously 

published a ‘‘Proposed Data Collection 

Submitted for Public Comment and 

Recommendations’’ notice on October 

21, 2024 to obtain comments from the 

public and affected agencies. CDC did 

not receive comments related to the 

previous notice. This notice serves to 

allow an additional 30 days for public 

and affected agency comments. 

CDC will accept all comments for this 

proposed information collection project. 

The Office of Management and Budget 

is particularly interested in comments 

that: 

(a) Evaluate whether the proposed 

collection of information is necessary 

for the proper performance of the 

functions of the agency, including 

whether the information will have 

practical utility; 

(b) Evaluate the accuracy of the 

agencies estimate of the burden of the 

proposed collection of information, 

including the validity of the 

methodology and assumptions used; 

(c) Enhance the quality, utility, and 

clarity of the information to be 

collected; 

(d) Minimize the burden of the 

collection of information on those who 

are to respond, including, through the 

use of appropriate automated, 

electronic, mechanical, or other 

technological collection techniques or 

other forms of information technology, 

e.g., permitting electronic submission of 

responses; and 

(e) Assess information collection 

costs. 

To request additional information on 

the proposed project or to obtain a copy 

of the information collection plan and 

instruments, call (404) 639–7570. 

Comments and recommendations for the 

proposed information collection should 

be sent within 30 days of publication of 

this notice to www.reginfo.gov/public/ 

do/PRAMain. Find this particular 

information collection by selecting 

‘‘Currently under 30-day Review—Open 

for Public Comments’’ or by using the 

search function. Direct written 

comments and/or suggestions regarding 

the items contained in this notice to the 

Attention: CDC Desk Officer, Office of 

Management and Budget, 725 17th 

Street, NW, Washington, DC 20503 or by 

fax to (202) 395–5806. Provide written 

comments within 30 days of notice 

publication. 

Proposed Project 

CryptoNet Case Report Form (OMB 

Control No. 0920–1360, Exp. 1/31/ 

2025)—Revision—National Center for 

Emerging and Zoonotic Infectious 

Diseases (NCEZID), Centers for Disease 

Control and Prevention (CDC). 

Background and Brief Description 

The Waterborne Disease Prevention 

Branch (WDPB) in the Division of 

Foodborne, Waterborne, and 

Environmental Diseases (DFWED) works 

to prevent domestic and global waterrelated diseases. The WDPB is 

comprised of five teams, including the 

Domestic Waterborne Disease 

Epidemiology and Response (WDER) 

Team, which focuses on the prevention 

and control of waterborne-related 

diseases and outbreaks in the United 

States. One of the diseases included in 

the team’s work is cryptosporidiosis, an 

acute diarrheal disease caused by 

infection with Cryptosporidium 

parasites. 

The Case Surveillance Program is a 

subunit within the Domestic WDER 

Team that focus on the data collection 

and management activities of five 

waterborne diseases, including 

cryptosporidiosis, in the United States. 

The Case Surveillance Program’s current 

scope of work includes modernizing 

data collection and management, 

enabling data connections, and 

improving public data access to aid 

public health action. 

CryptoNet is the first molecular 

tracking system for Cryptosporidium in 

the United States. To meet the needs of 

the CryptoNet and Case Surveillance 

Program, and the needs of local officials, 

the CryptoNet case report form (CRF) 

was developed. The CRF includes a set 

of data elements that can be used to 

identify exposures trends in outbreakand non-outbreak-associated 

Cryptosporidium cases, to generate 

hypotheses about the sources of 

infection in clusters or outbreaks, and to 

identify strategies to prevent and control 

Cryptosporidium cases, clusters, or 

outbreaks. 

Data from the CRF will be used by 

federal, state, and local public health 

officials responsible for conducting 

interviews with reported cases of 

cryptosporidiosis in their jurisdiction in 

order to systemically assess core 

exposure elements and risk factors 

among cases of cryptosporidiosis. 

Collected data will be used by CDC staff 

to inform cryptosporidiosis sporadic 


lotter on DSK11XQN23PROD with NOTICES1